#2-83E. Inflammation's Dual Edge: Rethinking Sarcopenia in Rheumatoid Arthritis (NatRevRheum, 2023)

How often do we consider the long-term functional implications of chronic inflammation beyond joint damage in our Rheumatoid Arthritis (RA) patients? This comprehensive review, "Rheumatoid sarcopenia - loss of skeletal muscle strength and mass in rheumatoid arthritis," addresses this critical co-morbidity, defining RA sarcopenia as the simultaneous loss of skeletal muscle strength and mass. It emphasizes that this condition is driven by RA disease activity, systemic inflammation, physical inactivity, and corticosteroid use, potentially leading to functional decline, increased fall risk, and higher mortality. Crucially, the authors highlight the complex duality of chronic inflammatory cytokines, particularly Interleukin-6 (IL-6). Persistent high levels of IL-6 may initially stimulate muscle regeneration and hypertrophy but ultimately drive significant muscle catabolism, providing a key insight into the pathology. While this review synthesizes vital information for clinical practice, it is important to critically evaluate the findings, recognizing the inherent limitation of generalizing results synthesized from potentially heterogeneous study designs in the original research papers1. This paper is essential for all physicians managing RA, underscoring that sarcopenia is an often-underestimated complication. It mandates a holistic treatment approach, advocating not just for strict inflammation control but also prioritizing non-pharmacological interventions, such as tailored exercise programs and nutritional management, to improve long-term functional status for our patients.

Citation: Nikiphorou E, Müller-Ladner U. Rheumatoid sarcopenia - loss of skeletal muscle strength and mass in rheumatoid arthritis. Nature Reviews Rheumatology. 2023.

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.